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Abstract 
 
Infective endocarditis (IE) is a life-threatening disease. Cerebral emboliza-
tion complicates the course in 10-40% of IE episodes. Aims of study were to 
investigate the frequency of cerebrovascular complications (CVC) in left-
sided IE and the influence of protective and risk factors with focus on anti-
platelet and anticoagulant therapy.  
 
CVC rate was examined by repeated magnetic resonance imaging of the 
brain and by assaying levels of brain damage markers in cerebrospinal fluid 
in 60 IE patients in paper I. The overall CVC frequency was 65%, with 35% 
of the patients experiencing neurological symptoms and 30% characterized 
as having clinically silent CVC. The risk of neurological deterioration during 
cardiac surgery after established cerebral embolism was low. 
 
In paper II the relationship between symptomatic CVC and established use 
of antiplatelet therapy was evaluated in 684 definite left-sided IE episodes. 
Antiplatelet agents were used by 23% of the patients. These patients were 
older and more often had a history of congestive heart failure. In 25% of all 
episodes a CVC was seen. There was no statistically significant difference in 
CVC rate between patients with and without previously established anti-
platelet therapy (24% vs. 25%, n.s.). Twelve-month mortality was signifi-
cantly higher for patients on previously established antiplatelet therapy in the 
univariable analysis (34% vs. 24%, OR 1.6, 95% CI 1.1-2.4), but after ad-
justment for covariables the use of antiplatelet therapy was no longer a risk 
factor. 
 
The association between ongoing warfarin therapy and CVC incidence in 
native valve endocarditis (NVE) was analyzed in paper III. Out of 587 NVE 
episodes 8% were seen in patients using warfarin on admission. Patients on 
warfarin suffered from CVC significantly less frequently than patients not on 
warfarin (6% vs. 26%, 0.2 95% CI 0.06-0.6). In a multivariable model S. 
aureus etiology (adjusted OR [aOR] 6.3, 95% CI 3.8-10.4) and vegetation 
length (aOR 1.04, 95% CI 1.01-1.07) were associated with higher CVC fre-
quency. Warfarin use (aOR 0.26, 95% CI 0.07-0.94), history of congestive 
heart failure (aOR 0.22, 95% CI 0.1-0.52) and previous IE episode (aOR 0.1, 
95% CI 0.01-0.79) conferred a lower risk of CVC. Cerebral hemorrhagic 
complications were few. 
 
Keywords: Infective endocarditis (IE), cerebral embolism, cerebrovascular 
complications, antiplatelet therapy, anticoagulation, warfarin, vegetation, 
Staphylococcus aureus, mortality 
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 Abbreviations 
aOR Adjusted odds ratio 
ASA Acetylsalicylic acid 
CHF Congestive heart failure 
CI Confidence interval 
CNS Central nervous system 
CoNS Coagulase-negative staphylococci 
CRP C-reactive protein 
CSF Cerebrospinal fluid 
CT Computed tomography 
CVC Cerebrovascular complication(s) 
GFAP Glial fibrillary acidic protein 
HACEK Haemophilus spp, Aggregatibacter actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella corrodens, Kingella spp 
IE Infective endocarditis 
INR International normalized ratio 
IQR Interquartile range 
IVDU Intravenous drug use 
MRI Magnetic resonance imaging 
MRSA Methicillin-resistant Staphylococcus aureus 
MSSA Methicillin-sensitive Staphylococcus aureus 
NFL Neurofilament protein - light chain 
NVE Native valve endocarditis 
OR Odds ratio 
PVE Prosthetic valve endocarditis 
ROC Reciever operating characteristic 
SD Standard deviation 
TEE Transesophageal echocardiography 
TIA Transient ischemic attack(s) 
TTE Transthoracic echocardiography 
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1 Introduction 
1.1 Infective endocarditis 
Infective endocarditis (IE) is a serious disease, universally fatal if unrevealed 
and untreated. IE can be defined as an endovascular microbial infection of 
cardiac structures and intracardiac foreign bodies. The commonly accepted 
pathogenetic theory is that IE results from a complex interaction between 
initially hemodynamically derived mechanical damage to the endocardial 
lining, preferably on the valvular cusps, and transient bacteremia with mi-
croorganism adhesion and escape from host defense mechanisms (1, 2). Di-
rect contact between blood and subendothelial components results in platelet 
and fibrin deposition and the formation of a coagulum. Circulating microor-
ganisms adhere to the coagulum and promote further enlargement of this 
infected structure, referred to as the vegetation (3, 4). These irregular excres-
cences on the cardiac valves or endocardium, composed of platelets, fibrin, 
microorganisms, and inflammatory cells, are characteristic but not patho-
gnomonic of IE. The detection of vegetations by echocardiography consti-
tutes one of the two major clinical criteria for IE, according to the Duke and 
modified Duke criteria (5, 6) (table 1). Continuous release of bacteria from 
the vegetations gives rise to the persistent bacteremia, the other cornerstone 
of IE. 
 
Microorganisms adherent to cardiac valves have been shown to avoid host 
defense mechanisms inside the vegetation through impaired infiltration of 
phagocytes into the vegetation (i.e. localized agranulocytosis) (7, 8), reduced 
phagocytic ability (4) and protection from the humoral immune response (9). 
Local extension of the infection, tissue damage and embolic spread of in-
fected material from valvular vegetations to distant organs give rise to the 
main complications of IE, congestive heart failure and embolic events. 
Causative microorganisms in IE are predominantly gram-positive bacteria, 
although a wide variety of pathogens can be found including gram-negative 
bacteria, fungi and rickettsiae. Viridans group streptococci and S. aureus are 
each found in approximately one third of IE episodes, enterococci in 10-
15%, and in 5-15% of episodes blood cultures are negative. 
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Table 1. Definition of infective endocarditis according to the modified Duke Criteria 
* Excludes positive cultures for coagulase-negative staphylococci and organisms that do not cause IE 
 
Definite infective endocarditis 
Pathologic criteria 
• Microorganisms demonstrated by results of cultures or histological examination of a 
vegetation, a vegetation that has embolized, or an intracardiac abscess specimen. 
• Pathologic lesions; vegetation, or intracardiac abscess confirmed by histologic exami-
nation showing active endocarditis. 
 
Clinical criteria 
• 2 major criteria 
• 1 major criterion and 3 minor criteria 
• 5 minor criteria 
Possible infective endocarditis 
• 1 major criterion and 1 minor criterion 
• 3 minor criteria 
Rejected 
• Firm alternate diagnosis explaining evidence of infective endocarditis. 
• Resolution of infective endocarditis syndrome with antibiotic therapy for ! 4 d. 
• No pathologic evidence of infective endocarditis at surgery or autopsy, with antibiotic 
therapy for ! 4 d. 
• Does not meet criteria for possible  infective endocarditis. 
_______________________________________________________________ 
 
Major criteria 
Blood culture findings positive for infective endocarditis 
• Typical microorganisms consistent with IE from 2 separate blood cultures: 
Viridans streptococci, Streptococcus bovis, HACEK group, or Staphylococcus aureus. 
Community-acquired enterococci, in the absence of a primary focus. 
• Microorganisms consistent with IE from persistently positive blood cultures 
(at least 2 positive cultures of blood samples drawn >12 h apart; or 3 or most of > 4 
separate cultures of blood (with first and last sample drawn > 1 h apart). 
• Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titer       
> 1:800). 
Evidence of endocardial involvement (echocardiographic findings positive for IE)  
• Oscillating intracardiac mass on valve or supporting structures, in the path of regurgi-
tant jets, or on implanted material in the absence of an alternative anatomic explanation. 
• Abscess. 
• New partial dehiscence of prosthetic valve.  
• New valvular regurgitation. 
Minor criteria 
• Predisposition: predisposing heart condition, or intravenous drug use. 
• Fever, temperature " 38°C. 
• Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneu-
rysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway´s lesions. 
• Immunologic phenomena: glomerulonephritis, Osler´s nodes, Roth´s spots, rheumatoid 
factor. 
• Microbiological evidence: positive blood culture but does not meet a major criterion*.  
10
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1.2 Historical aspects 
One of the first descriptions of IE dates back to 1646 and was by Rivière, 
who compared the autopsy findings of cardiac vegetations with “a cluster of 
hazel nuts”. The term “vegetation” was first used by Corvisart in 1806, and 
in 1852 Kirkes attributed systemic emboli to vegetations on heart valves. 
Virchow defined this phenomenon as embolism, and in 1881 Netter de-
scribed the novel practice of culturing blood from patients with endocarditis. 
In 1885, Osler described the triad of preexisting “chronic valvulitis”, irregu-
lar fever, and embolism in his famous ”Gulstonian Lectures on Malignant 
Endocarditis” (10), which later established his reputation as the father  of the 
clinical entity endocarditis (11). In the 1930s the first attempts to treat IE 
with the antimicrobial agent sulphonamide were performed, but not until 
penicillin became available for clinical use in 1942 could successful treat-
ment be achieved. It was first published by Loewe et al. in 1944 (12) and, 
interestingly, this and his next report (13) were both on the combination 
therapy of penicillin and heparin. In subsequent studies of IE heparin was 
associated with a high risk of cerebral hemorrhage (14-16) and anticoagula-
tion proved unnecessary when adequate penicillin doses were used (17). The 
clinical diagnosis of IE was thus possible for more than 50 years before ef-
fective treatment could be given. The medical student Alfred S. Reinhardt 
described the patient perspective on this diagnosis in 1931 in the patient 
record he kept on himself when he sufferd from IE during the last 6 months 
of his life (figure 1). 
 
Figure 1. Summary of the patient record of Alfred S. Reinhardt during 1931 (18) 
Reinhardt’s illness 
• Aortic insufficiency after rheumatic fever by the age of 13. Blood pressure 
160/00. Cor bovinum. 
• April: Acute tonsillitis develops. 
• May: Salvos of palpitations occur on exertion; petechial shower is observed 
on left arm. 
• July: Pain develops in right knee; Reinhart is admitted to Peter Bent Brigham 
Hospital July 23. 
• August: Blood culture is positive for Streptococcus viridans Aug. 2. Splenic 
infarction occurs Aug. 24. 
• September: Reinhart is transferred to Boston City Hospital Sept. 11. Enlarging 
spleen, anemia, painful cutaneous nodules, showers of petechiae, painful 
muscles and joints are noted. Another splenic infarction occurs Sept 25. 
• October: Attacks of transient aphasia begin Oct. 18. Right hemiplegia devel-
ops Oct. 21. On Oct. 26 pulmonary edema develops and Reinhart dies. 
•  
 Freely based on K. M. Flegel, Dept of Medicine, McGill University, 
Montreal,Canada 
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1.3 Epidemiology 
The annual incidence of IE in Sweden is estimated to be 5.9 cases per 
100,000 inhabitants (19), as compared with estimated incidences of 1.9 to 
9.6 cases per 100,000 individuals found in other studies (20-27). The inci-
dence of IE is thought to have remained stable over the last three decades 
(20, 28) but international data indicate that the epidemiology of IE is chang-
ing. In recent studies, IE patients are found to be older, have more prosthetic 
valve (PVE) or device associated IE episodes, and more often undergo car-
diac surgery during the period of antibiotic treatment (19, 20, 29-33). A shift 
toward a higher frequency of S. aureus IE has both been reported (34, 35) 
and also questioned (28). These diverging data mirror the influence of refer-
ral bias as well as differences in living conditions, genetic factors and bacte-
rial resistance among different IE populations studied (34, 36, 37). 
 
In-hospital mortality in patients with IE reported to the National Swedish 
Endocarditis Registry 1995-2007 was 12% (pers comm L. Olaison).  Similar 
in-hospital mortality rates of 10–18% have been found in other studies (21, 
26, 38-42). Mortality rate was reduced after the introduction of thoracic sur-
gery in the 1960s and 70s while reports on mortality in IE during the last two 
to three decades yield conflicting results (28, 29, 39, 43). This might reflect 
the contemporary epidemiological changes towards older ages, more comor-
bid conditions, device-related episodes and more virulent microorganisms 
(25). 
1.4 Gender aspects 
In most published studies IE occurs more frequently in men than in women 
(22, 29, 35, 44), while female dominance was found in a prospective cohort 
study in Gothenburg 1984-88 (19). Results from some earlier studies of IE 
also show more even sex distribution (5, 45-47) while in Osler’s original 
report there was male predominance (10). Several studies indicate that 
women diagnosed with IE are older than men (19, 35) while data on age is 
not reported in most publications. In most studies cerebral complications are 
reported in similar frequencies in both men and women with IE (47-52), 
while frequencies are not presented as separate sex data in other studies (53, 
54). In one study, Roder et al. found a trend towards more neurological 
manifestations in women with S. aureus IE than in men with S. aureus IE 
(55), and S. aureus etiology has been found more often in women than in 
men with IE (34, 46). Lower surgery rates and/or higher in-hospital mortality 
have been reported among women as compared with men (50, 56-58) but 
interpretation was confounded by differences in age and comorbid condi-
tions in some studies. 
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It is not known whether the observed demographic and clinical differences 
between women and men with IE reflect varying rates of comorbid condi-
tions or inherent physiological differences, but may partly be explained by 
diagnostic, referral, or treatment bias (19). Other potential explanations have 
been extrapolated from animal models, suggesting that estrogen is protective 
against endothelial damage (59). In addition, human studies have shown that 
women are less likely than men to develop sepsis after traumatic hemor-
rhagic shock (60). Women also tend to develop heart disease later in life 
than men (61, 62).  
1.5 Embolic events 
Embolization from vegetations is a characteristic feature of IE, and compli-
cates the course in 20-60% of IE episodes (58, 63-66), with the highest num-
bers seen in studies where asymptomatic embolism has also been investi-
gated. Embolic events can cause distinct symptoms, but silent embolism has 
also been well documented (63, 66). The incidence of embolism has not 
been possible to define with certainty. The most frequent localization of 
embolism in left-sided IE is the cerebral vascular bed, which is involved in 
up to 70% (67) of embolic events. Right-sided IE typically embolizes to the 
lungs (68, 69). A considerable number of silent embolic events have been 
reported to involve the spleen and the kidneys (63). Embolic events, espe-
cially cerebral emboli, have generally been considered to have deleterious 
implications on the prognosis in IE (70, 71). 
1.6 Neurological complications  
The majority of neurological complications are established before IE is di-
agnosed (47, 49, 53, 63, 72). The rate of new embolic events (cerebral and 
peripheral) has been shown to decrease rapidly after the initiation of effec-
tive antibiotic therapy (27, 48, 73, 74). Factors predictive of embolization are 
not fully understood but higher incidence of embolic events has been corre-
lated in different studies including adult IE patients, to presence of vegeta-
tions on echocardiography as well as to vegetation size and mobility charac-
teristics, S. aureus etiology, mitral valve involvement, younger age and 
higher CRP levels (49, 54, 63-65, 75-79). Most studies also reveal higher 
case fatality rates in IE episodes complicated by neurologic events (10, 47, 
49, 55, 72, 80-83).  
 
Central nervous system (CNS) symptoms in IE are variable, and attempts to 
divide these manifestations into different pathogenetic categories have been 
made: embolization causing ischemic and/or hemorrhagic infarction, pri-
13
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mary intracerebral bleeding, subarachnoid bleeding, mycotic aneurysm, in-
fection of the brain or meninges and toxic or immune-mediated injury, en-
cephalopathy and psychiatric manifestations (47, 84-87). It is well docu-
mented that IE patients with cerebral involvement often exhibit more than 
one type of lesion and/or neurological sign (47, 88-91) although they may 
also be asymptomatic (56, 66, 72). In a carefully described material of 17 
patients dying from IE in the 1930s, the fundamental pathological change in 
the brain was diffuse embolic meningoencephalitis, from which various 
clinical manifestations arose (92). Pruitt et al. postulated that cerebral infarc-
tion, micro- and macroabscess formation, septic vasculitis and mycotic aneu-
rysms represent a continuum, and that the advent of computed tomography 
(CT) and magnetic resonance imaging (MRI) has made the clinical distinc-
tion between syndromes less clear (93). Encephalopathy with impaired con-
sciousness or delirium and meningism have also been argued to be of septic 
embolic origin (77, 94). Lerner concluded that infected emboli account for 
all neurological complications in IE (mycotic aneurysm, intracerebral bleed-
ing, meningitis/meningoencephalitis, and brain abscess) additional to caus-
ing pure ischemic lesions (95). Roder et al. arrived at the opinion that the 
attempt to prove the precise nature of a neurological complication is inher-
ently connected with difficulties (55) . 
 
Ischemic infarction is the most common neurological complication in IE 
occurring in 9–28% of all IE episodes (47-49, 54, 72, 78). Large emboli 
preferably lodge in the middle cerebral artery territory, resulting in hemipa-
retic symptoms of varying degree. The clinical syndromes seen with micro-
embolic punctuate cerebral infarctions are variable, often referred to as an 
altered level of consciousness or embolic encephalopathy. About half of IE 
episodes with cerebral emboli are described as having concomitant periph-
eral emboli (47). Intracranial hemorrhage occurs in 2-7% of patients with IE 
(47, 49, 54, 72, 82, 91, 96) and three different mechanisms are thought to 
prevail, namely rupture of mycotic (infectious) aneurysm, pyogenic arteritis 
and hemorrhagic transformation of initially bland infarction. Anticoagulant 
therapy has been associated with a higher risk of hemorrhagic complications 
in IE (47, 88, 96, 97).  
 
The incidence of meningitis in IE varies from 3-16% in different studies and 
is, when it occurs, an early feature of the complex clinical manifestations of 
IE. Meningitis is most frequently seen with S. aureus as the causative patho-
gen, but also in IE caused by other pathogens. The detected rate of meningi-
tis in different studies depends to a large extent on the frequency of lumbar 
punctures performed in the specific study setting. More than one third of 
patients with meningitis experience additional neurological complications 
(98). The availability of better and non-invasive brain imaging methods have 
reduced the proportion of IE patients examined by lumbar puncture and 
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cerebrospinal fluid (CSF) analysis, since isolated meningism is seldom the 
only initial neurological symptom. This is illustrated by two studies by Pruitt 
et al. made at different time periods, the first with IE patients from 1964 to 
1973 when 85% of the patients with neurological symptoms underwent lum-
bar puncture, the second with patients from 1988 to 1992, when the corre-
sponding figure was 43%. In the first study, the incidence of CSF anomalies 
indicative of meningitis was 16% of all IE cases, in the second it was 4% 
(47, 93). CSF culture is positive only in a minority of patients with IE asso-
ciated meningitis (47, 49, 55, 82). Aseptic meningitis, often with moderately 
increased numbers of white blood cells in the CSF is thought to prevail, al-
though this concept has been questioned (92, 98). 
 
It is widely accepted that mortality in patients with IE is reduced in a consid-
erable subset of patients by early surgical intervention (80, 99-102). The 
safety of cardiac surgery in IE patients suffering from cerebral complications 
is an important question since cardiopulmonary bypass is suspected to ag-
gravate preexisting neurological deficits and to carry an increased risk of 
secondary cerebral hemorrhage due to heparinization. In the absence of a 
hemorrhagic cerebral manifestation, valve replacement has been considered 
resonably safe when performed at least 72 h after the cerebral event, while 
patients with a recent hemorrhagic cerebral complication are anticipated to 
have an unacceptably high risk of intracranial bleeding during early cardiac 
surgery (103). In a study by Ruttmann et al. (52) the suspected risk of secon-
dary hemorrhage in IE patients undergoing cardiac surgery despite preopera-
tively established cerebral embolism was very low, and the authors recom-
mended early surgical procedure for IE when indicated also after stroke. 
1.7 Antiplatelet therapy 
The pharmacological effects of salicylic acid have been known since ancient 
times. Hippocrates, the father of modern medicine, made the first recorded 
descriptions of the therapeutic benefits of extract of willow bark in the fifth 
century B.C. Salicylate-rich willow bark extract was used for its analgesic 
and anti-rheumatic effects. By the end of the nineteenth century German 
chemists had managed to synthesize acetylsalicylic acid (ASA) by acetyla-
tion of salicylic acid, and this drug, subsequently named aspirin, soon be-
came the most sold medication worldwide. In 1908 ASA was introduced in 
the Swedish Pharmacopeia and became a formal part of Swedish pharmacol-
ogical history.  
 
The analgesic, antipyretic and anti-inflammatory effects of ASA were 
known long before its mechanisms of action through inhibition of cyclooxy-
genase in the prostaglandin synthesis was elucidated by Vane and coworkers 
15
 18 
in the late 1960s (104). The antiplatelet era of ASA began with the observa-
tion that patients with regular ASA use had fewer heart attacks than ex-
pected, and later the use of ASA to reduce the rate of stroke and myocardial 
infarctions was approved. This effect is mediated by irreversible inhibition 
of cyclooxygenase and termination of production of tromboxan in platelets, 
and requires lower doses than used to produce the analgesic and anti-
inflammatory effects. ASA reduces the relative risk of stroke, myocardial 
infarction and vascular death by 25% in high risk patients and has wide-
spread use as primary and secondary prophylaxis (105).  
 
The potential role of antiplatelet agents as adjunctive therapy in IE has pro-
voked considerable interest, and a complex pattern of mechanisms involving 
platelets in the evolution of IE has been outlined (106-108). Advantageous 
effects of these agents have been shown under experimental conditions in 
several studies mainly concerning S. aureus IE (109-113). Other studies 
have failed to demonstrate such positive effects (114, 115). The results of 
prospective human treatment studies (116, 117) and recently published co-
hort studies (51, 53, 118, 119) are contradictory. Occasional reports of anti-
platelet drug use in neonatal IE (120) and bovine IE (121) have opened up 
for further hypothesizing, but international treatment guidelines on IE do not 
generally include comments concerning the use of antiplatelet agents. 
 
Newer antiplatelet drugs have been developed, of which clopidogrel has 
been shown to be significantly more effective than ASA in reducing the risk 
of stroke, myocardial infarction, or vascular death in patients with athero-
sclerotic vascular disease (122). Clopidogrel blocks activation of platelets by 
another mechanism and has fewer upper gastrointestinal side effects than 
ASA. Bleeding, a common complication with antiplatelet drugs irrespective 
of mechanism of action, has also proven to be less frequent with clopidogrel. 
1.8 Anticoagulant therapy 
Heparin 
In 1916 McLean first observed that an extract of dog liver contained a sub-
stance that retarded the coagulation of blood in vitro. This substance was 
named “heparin” by Howell in 1918 and was tried in humans in 1935 (123). 
Its subsequent clinical use in the prevention and treatment of venous throm-
boembolism was introduced early in Sweden (124). In 1941, McLean evalu-
ated the use of heparin in IE patients (125) and found that heparin treatment 
did not lead to improvments and resulted in a high proportion of fatal cere-
bral hemorrhages. Contrary to this were the results of combination therapy 
with heparin and penicillin found to be succesful by Loewe et al. (12). In 
still other studies the addition of anticoagulant therapy proved unnecessary 
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when adequate penicillin doses were used (45). Most authors (85, 126) have 
since discouraged the routine use of anticoagulant therapy in patients with 
IE. 
 
Heparin is a naturally occurring glycosaminoglycan, the main function of 
which is to inhibit the coagulation of blood by activating antitrombin III. 
Subsequent inactivation of the coagulation cascade is seen mainly through 
inhibition of thrombin (factor II) and factor X. Low molecular weight hepa-
rin is composed of depolymerized heparin salts with lower molecular weight, 
longer biological half-life and more predictable effects on the coagulation 
system. Both unfractionated and low molecular weight heparins are contra-
indicated during septic endocarditis according to Swedish pharmaceutical 
recommendations (www.fass.se), owing to the risk of cerebral bleeding dur-
ing IE.  
Coumarin 
In the early 1920s a previously unknown disease in cattle was recognized in 
the United States and Canada. The animals died of uncontrollable bleeding 
from minor injuries or internal hemorrhage. The cause of this condition 
proved to be ingestion of spoiled sweet clover (Melilotus officinalis) that 
functioned as a potent anticoagulant. The affected cattle had prolonged clot-
ting time, owing to profound prothrombin deficiency. Coumarin was, at this 
time, a known component of sweet clover, causing the combination of a 
sweet smell and a bitter taste, and it was commercially used to scent cheap 
tobacco, artificial vanilla and perfumes. Not until 1939, when Karl Link and 
associates isolated the hemorrhagic agent from sweet clover, the association 
between coumarin and sweet clover disease was revealed (127). Coumarin 
itself , like other natural coumarins, is atoxic, but in moldy hay it is oxidized 
to hydroxycoumarin and linked to another coumarin molecule, thus forming 
a dicoumarol with potent anticoagulant effects. This compound was subse-
quently synthesized and the clinical use of dicoumarol began in 1941. As 
early as 1948 a randomized study sponsored by the American Heart Associa-
tion concluded the beneficial effects of dicoumarol in myocardial infarction 
(128). Dicoumarol was, however, a weak and unpredictable drug and another 
more potent coumarin, given the name warfarin, was patented 10 years later. 
The initial use of warfarin was as a rat poison but the substance soon proved 
more reliable than dicoumarol in the clinical setting and was commercially 
introduced in 1954. 
 
Warfarin is a synthetic anticoagulant substance and works through competi-
tive inhibition of vitamin K reductase. This enzyme recycles oxidated vita-
min K after vitamin K has participated in the carboxylation of several blood 
coagulation proteins, mainly prothrombin (factor II), factors VII, IX and X, 
as well as other proteins involved in the blood clotting system. The decar-
boxylated coagulation factors produced in the presence of warfarin are bio-
17
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logically inactive and successively replace the active clotting factors in the 
circulatory system, explaining the slow onset of the anticoagulant effect of 
warfarin. Warfarin and related drugs are referred to as vitamin K antagonists, 
and their effects can be reversed with vitamin K or by transfusion of coagu-
lation factors. The inter- and intraindividual therapeutic sensitivity to war-
farin is variable and the intensity of the anticoagulant effect must be fol-
lowed with standardized measurements of the prothrombin time (interna-
tional normalized ratio, INR). 
1.9 Neurochemical markers of brain damage 
Measurement of concentrations of organ-specific proteins in body fluids is 
well established in various medical fields, e.g. analysis of serum levels of 
troponin and creatine kinase in patients with suspected myocardial infarction 
or alanine aminotransferase to evaluate liver cell damage. Specific proteins 
that are found in high concentrations in CNS but in negligible concentrations 
in other organs can be used to assess various types of brain injury. The neu-
rochemical marker proteins are specific for different CNS cell types and/or 
for distinct cellular components. Of the two brain damage markers used in 
this thesis (Paper I) the light chain of the neurofilament protein (NFL) is an 
established marker of neuronal/axonal damage, and glial fibrillary protein 
(GFAP) is a marker of astroglial cell injury. Ischemic infarctions and other 
types of acute or chronic brain diseases provoke brain cell destruction and 
leakage of marker proteins into CSF. NFL and GFAP are analyzed in clinical 
praxis at the Sahlgrenska University Hospital.  
 
The neurofilament is the main structural component of the neuronal cy-
toskeleton. It is abundant in axons relative to nerve cell somas and in large 
myelinated axons (129). The neurofilament is composed of a triplet protein 
of which the light subunit (NFL) is the essential component. It is used as a 
marker of neurodegeneration, particularly of axonal damage. Following 
acute parenchymatous CNS damage, the levels gradually increase, with a 
maximum after a few weeks and normalization over a period of months. The 
late increase is related to the release of NFL from injured axons subsequent 
to damage of neuronal soma. Measurements of CSF-NFL as a marker of 
axonal damage show increased values after cerebral infarction (130-132) and 
in various other conditions with neuronal damage (131, 133-135). 
 
Glial fibrillary acidic protein is a structural protein found almost exclusively 
in glial cells of the CNS. In astrocytes, GFAP builds up the intermediate 
filament, which is the main cytoskeleton structure (136). Increased levels of 
GFAP in CSF have been demonstrated in two principally different situa-
tions: (i) associated to astrogliosis and (ii) after acute CNS injuries with dis-
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integration of glial cells. Astrogliosis is a reactive proliferation, and hyper-
trophy of astrocytes with increased intracellular amounts and extracellular 
release of GFAP to CSF. Astrogliosis is an unspecific reaction seen follow-
ing brain injury, in inflammatory and certain chronic conditions, but also 
during ageing (137). Modest increases in CSF-GFAP levels are seen in mul-
tiple sclerosis (133) and normal pressure hydrocephalus (138). After acute 
parenchymatous CNS damage, an increase in CSF-GFAP can be detected 
from days 1-2, with concentrations returning to normal within less than three 
weeks (139). The levels reflect the extent of the injury and are high after 
large cerebral infarctions (139, 140), in patients with herpes encephalitis 
(134) and after subarachnoid hemorrhage (141).  
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2 Aims of the study 
1. To study the incidence of symptomatic and silent cerebral complications 
during episodes of left-sided infective endocarditis using sensitive diag-
nostic methods (Paper I). 
 
2. To study the influence of protective factors and risk factors for cere-
brovascular complications in left-sided infective endocarditis (Paper I-
III). 
 
3. To study the relationship between previously established daily antiplate-
let therapy and cerebrovascular complications and mortality in left-sided 
definite infective endocarditis (Paper II). 
 
4. To study the association between ongoing oral anticoagulant therapy and 
cerebrovascular complications in patients with left-sided native valve 
endocarditis (Paper III).  
 
 
 
 
20
 23 
3 Patients and methods 
3.1 Patients  
Adult patients with left-sided possible or definite IE according to the Duke 
modified criteria (6) at three tertiary care centers in Sweden and Denmark 
were included. Altogether, 866 episodes of IE in 837 patients were consecu-
tively enrolled in the study from January 1, 1996 to January 31, 2008 in 
Gothenburg (papers I–III) and from October 1, 2002 to January 31, 2008 in 
Copenhagen (papers II–III). Patients with isolated right-sided IE were ex-
cluded from the analysis owing to the inherently low risk of cerebral embo-
lism in such episodes (68). Thus the remaining 797 episodes of left-sided IE 
in 771 patients were the total study cohort as illustrated in figure 2. In paper 
I, only patients from Sweden were included, and the inclusion period was in 
two intervals between June 1, 1998 and January 31, 2005. During the final 
year of that study, patients from the Department of Infectious Diseases at 
Skaraborg Hospital, Skövde, Sweden were also included.  
 
The Department of Infectious Diseases, Sahlgrenska University Hospital, 
Gothenburg, Sweden, serves the Gothenburg area, with about 600 000 in-
habitants, as both first-line and tertiary care center for IE patients. In addi-
tion, the Departments of Infectious Diseases and Cardiothoracic Surgery at 
the Sahlgrenska University Hospital serve as tertiary referral center for IE 
patients from other hospitals in western Sweden (Västra Götaland regionen) 
with about 1.5 million inhabitants. The Department of Cardiology, Gentofte 
University Hospital, Copenhagen, Denmark and the Department of Cardiol-
ogy, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Den-
mark provide care for patients with IE in the eastern part of Denmark with a 
catchment area of 2.4 million inhabitants. These centers are the only ones in 
the area receiving IE patients, and are thus responsible for both basic and 
highly specialized care. Patients with diagnosed IE are transferred to these 
centers and there are cardiothoracic surgery departments in both hospitals.  
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Figure 2. Distribution of patients with infective endocarditis included in the studies. 
IE: infective endocarditis, NVE: native valve endocarditis, PVE: prosthetic valve 
endocarditis. 
* Referred to in text as ”total cohort”. 
** Inclusion period: June 1998-April 2001, September 2002-January 2005. Two 
patients from the Department of Infectious Diseases at Skaraborg Hospital, Skövde, 
Sweden included in 2004.  
. 
3.2. Study design 
The studies were carried out as observational cohort studies. In paper I, pa-
tients with high clinical suspicion of IE were enrolled irrespective of neuro-
logical symptoms. Symptomatic and silent (asymptomatic) CVC during the 
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present IE episode was the primary outcome variable. Patients underwent 
repeated physical and neurological examinations during hospitalization. 
Magnetic resonance imaging (MRI) of the brain was performed during the 
first 10 days of antibiotic treatment and a follow-up MRI after 2-3 months. 
Lumbar puncture with analysis of CSF was done during the first and fourth 
weeks of treatment if no contraindications were found and the patient con-
sented. The study was approved by the ethics committee of the University of 
Gothenburg (L 077-98).  
 
In papers II–III consecutive patients with IE treated in the participating cen-
ters were eligible for study entry. Patients enrolled prospectively in the study 
were followed according to local protocols including uniform treatment 
regimens, clinical evaluation procedures and collections of specimens in-
cluding blood cultures. Study participants were treated in regular care at the 
Cardiology Department (Denmark) or the Infectious Diseases Department 
(Sweden) and consultations with other specialists including thoracic sur-
geons were performed regularly. Demographic and clinical characteristics 
including age, sex, presence of comorbidities, ongoing medication, cardiac 
rhythm, presence of prosthetic valve, or pacemaker/intravascular device and 
duration of symptoms prior to admission were recorded. Blood cultures, 
biochemical blood tests, radiological, electrocardiographic and echocardio-
graphic examinations as well as antibiotic treatment, and frequency, timing 
and type of surgical treatment were recorded. Primary outcome variables 
were cerebrovascular complications (CVC) during IE, and in-hospital and 
12-month mortality.  
3.3 Methods 
Magnetic resonance imaging (Paper I) 
The MRI protocol contained T1, T2, and PD-weighted images before and 
after the administration of a gadolinium contrast medium. MR angiography 
was not routinely performed. Diffusion-weighted MRI was not available 
when the study began and is therefor not included in the protocol. If contra-
indications for MRI were present, computed tomography (CT) of the brain 
with and without contrast was performed instead. MRI findings were evalu-
ated directly by the supervising neuroradiologist and later reevaluated by one 
of two experienced neuroradiologists blinded to the clinical and neurological 
status of the patients. Identification of acute or subacute ischemic, hemor-
rhagic or infectious lesions as well as changes between the two subsequent 
neuroradiological investigations in each patient were considered in the diag-
nosis of a cerebral complication. Each patient served as his/her own control, 
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and findings with a temporally consistent association were considered re-
lated to the present IE episode. 
Cerebrospinal fluid analyses (Paper I) 
The CSF analyses included bacterial culture, cell counts, and determination 
of glucose and albumin levels. Polymorphnuclear leukocytes >5 x 106 
cells/mL CSF were considered diagnostic of meningitis (49, 54), while iso-
lated elevation of monomorphnuclear leukocytes was not.  
 
CSF concentrations of the neurochemical brain damage marker NFL (neuro-
filament protein light chain) were analyzed using a sandwich ELISA as pre-
viously described (131). The sensitivity of the assay was 125 ng/L and the 
standard curve ranged from 125 to 16 000 ng/L. Values are age dependent 
and were regarded as normal if the level of CSF-NFL was <250 ng/L for 
patients aged <59 years, <380 ng/L for patients aged 60-69 years and <750 
ng/L for patients aged >70 years.  
 
GFAP (glial fibrillary acidic protein) was measured with a previously de-
scribed ELISA procedure (137). The standard curve ranged from 32-16 000 
ng/L and the sensitivity of the assay was 16 ng/L. Values are age dependent 
and were regarded as normal if the level of CSF-GFAP was <750 ng/L for 
patients aged 20-59 years, <1250 ng/L for patients aged >60 years. CSF-
NFL and CSF-GFAP reference levels were based on measurments from 141 
neurologically healthy individuals aged 18-83 years. 
Echocardiography 
Transthoracic and transoesophageal echocardiography were performed using 
standard techniques in all patients included in papers I-III with the exception 
of 17 cases where only TTE was performed. Seven of these were classified 
as possible IE due to lack of conclusive findings on TTE, four were definite 
through autopsy findings, one through peroperative findings, four through 
detection of vegetations on TTE, and one classified as definite based on five 
minor criteria.  
 
Evidence of endocardial involvement detected using echocardiography was 
classified according to the modified Duke criteria (6). Vegetations were clas-
sified by location and maximum size. Mobility characteristics were consid-
ered as an insufficiently standardized variable in the absence of systematic 
reevaluation of the echocardiographic examinations and were therefore not 
included in any of the analyses. Paravalvular engagement of the infection 
was defined as the presence of intracardiac abscesses and/or pseodoaneu-
rysm formation or new periprosthetic regurgitation in PVE.  
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3.4 Definitions 
Case definition 
A prospectively identified episode of left-sided IE satisfying the modified 
Duke criteria (6) of possible or definite IE constituted a defined case. Possi-
ble IE episodes were included if treatment was given in accordance with IE 
treatment guidelines or, in cases of in-hospital death, intended to be given. In 
cases included prior to the year 2000 the modified criteria were applied ret-
rospectively. Childhood cases were not included (<15 years). Left-sided IE 
cases included episodes with combined right and left-sided engagement of 
the infection.  
Microbial etiology 
The causative agents were divided into seven different categories of micro-
bial etiology: Staphylococcus aureus including methicillin-sensitive (MSSA) 
and methicillin-resistant (MRSA) strains; viridans group streptococci includ-
ing Streptococcus bovis; coagulase-negative staphylococci; Enterococci spp; 
other streptococci including groups A, B, C, G and pneumococci, miscella-
neous microorganisms including HACEK (Haemophilus spp, Aggregatibac-
ter [former Actinobacillus] actinomycetemcomitans, Cardiobacterium 
hominis, Eikenella corrodens, Kingella spp), Candida spp and other bacte-
ria; and episodes with negative blood cultures. 
Cerebrovascular complications 
Cerebrovascular complications (CVC) included ischemic and hemorrhagic 
infarctions, intracerebral and subarachnoid hemorrhages, cerebral mycotic 
aneurysms, transient ischemic attacks (TIA), and cerebral infections includ-
ing brain abscesses and culture-positive and culture-negative meningitis. A 
TIA was defined as a focal neurological sign or symptom of sudden occur-
rence and resolution within 24 h.  
 
Cerebral events occurring in the prediagnostic period and during treatment 
of the studied IE episode were the focus of this thesis, while later neurologi-
cal complications were not systematically registered. Diagnosis of CVC was 
based on repeated physical and neurological examinations, neuroimaging 
recordings and/or lumbar puncture. Cerebral CT or MRI was performed in 
all episodes with neurological symptoms except six cases in the total study 
cohort. In five cases presenting with meningism, only lumbar puncture with 
CSF analysis was performed and in one case of early in-hospital death owing 
to cardiac failure, a clinical diagnosis of ischemic stroke was made. In pa-
tients without neurological symptoms no routine cerebral CT or MRI was 
performed. 
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Mortality 
In-hospital mortality was defined as death occurring during the index hospi-
talization for IE. Twelve-month mortality (paper II) included death occurring 
during the initial hospitalization and the follow-up period.  
Antiplatelet therapy 
Antiplatelet therapy (paper II) included acetylsalicylic acid (ASA), dipyra-
midole or clopidogrel, or combinations of these agents. Doses were re-
corded. No patients were treated with ticlopidine. Previously established use 
was defined as prescribed and reported daily use of an antiplatelet agent 
prior to admission to hospital.  
Anticoagulant therapy 
Ongoing oral anticoagulant therapy (paper III) was defined as prescribed and 
reported continuous use of an oral anticoagulant prior to admission for IE. 
The only oral anticoagulant agent used by study patients was warfarin. Dis-
continuation of warfarin was registered, as was replacement therapy with 
heparin or low molecular weight heparin.  
3.5 Statistics 
Comparisons of continuous data were performed using Mann-Whitney U 
test, student´s t test or one-way ANOVA  when accurate.  For categorical 
variables the Chi-square test or Fisher’s exact test was used. Continuous 
variables were expressed as median and interquartile range (IQR) or mean 
and standard deviation. All statistical tests were two-tailed and p-values less 
than 0.05 considered statistically significant. Univariable risk factor analysis 
was performed using Fisher’s permutation test (142) in paper I and univari-
able logistic regression in papers II and III. Multivariable risk factor analysis 
was performed using logistic regression models in papers I-III. The multi-
variable models contained traditional risk factors, such as age and sex, as 
well as factors statistically significant in the univariable models in each 
study. In paper I the discriminating ability of variables in the multivariable 
model was tested using receiver operating characteristic (ROC) curves. The 
area under the ROC curve equals the probability that a randomly chosen 
individual with a certain risk factor will have a higher value of the discrimi-
nating variable than a randomly chosen individual without this risk factor. 
The analysis is considered to have excellent discrimination if the area under 
the ROC curve is in the interval 0.8-0.9 (143). 
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4 Results and discussion 
4.1 Demography 
Baseline characteristics of the 797 episodes of left-sided IE in the total study 
cohort are shown in table 2. Infective endocarditis fulfilling definite criteria 
was seen in 86% of the episodes. The prevalence of intravenous drug use 
(IVDU) was generally low among study patients but, as expected, a higher 
rate of IVDU was reported among patients with S. aureus IE compared to 
patients with IE caused by other pathogens (7% vs. 2%, p=0.007). Prosthetic 
valve endocarditis was seen in 26% of the patients and a history of conges-
tive heart failure in 23%. Other underlying conditions such as diabetes (22% 
vs. 10%, p<0.001), immunosuppression (15% vs. 9%, p=0.026) and hemo-
dialysis (9% vs. 2%, p<0.001) were more prevalent in patients with S. 
aureus IE. Cardiac surgery during antibiotic treatment was performed in 
39% of the patients in the total cohort. 
Age  
Mean and median age of patients in the total cohort was 63.5 (SD 15.9) and 
66 (IQR 53-76) years, with a range of 15-99 years. A similar age span was 
seen in the National Swedish Endocarditis Registry (57, 144) and in other 
modern IE cohorts in the industrialized world (24, 31, 118, 145), while the 
median age in patients in a large worldwide multicenter study performed by 
the International Collaboration on Endocarditis (ICE) was slightly lower 
(42). These aged populations contrast the IE cohorts studied in the mid-
1900s (45, 146) and in developing countries today (147, 148) with mean 
ages of 40 years or less. The numbers of patients divided by 10-year age 
intervals are shown in figure 3. The number of IE episodes increased in each 
10-year age group up to 80 years of age, but no incidence rates were calcu-
lated owing to lack of denominator data. However, in a study from Gothen-
burg 1984-1988 also including retrospectively identified cases (19) median 
age was still higher, 70 years, and the calculated incidence continued to in-
crease beyond 80 years of age. 
 
Median age (67 years) among patients included in paper I was in accordance 
with the median age of the total cohort despite the different inclusion proce-
dure in that part of the study. Among definite IE cases (paper II), the sub-
group of patients on previously established antiplatelet therapy had a median  
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Table 2. Demographic and clinical characteristics of 797 left-sided infective endo-
carditis episodes. 
 
 Study patients, left-sided 
IE episodes 
n=797  (%) 
Definite infective endocarditis 684 (86) 
Female sex  264 (33) 
Age (years) median (IQR) 66 (53-76) 
Diabetes mellitus 100 (13) 
Hemodialysis 28 (4) 
History of congestive heart failure 180 (23) 
Previous infective endocarditis 76 (10) 
Atrial fibrillation 143 (18) 
Intravenous drug use 27 (3) 
History of malignancy 61 (8) 
Immunosuppression 83 (10) 
Aortic valve infection 498 (62) 
Mitral valve infection 396 (50) 
Dual valve infection 97 (12) 
Prosthetic valve infection 210 (26) 
CRP maximum level (mg/L) median (IQR) 117 (65-200) 
Duration of antibiotic therapy (days) median (IQR) 32 (27-42) 
Cardiac surgery during antibiotic treatment 312 (39) 
IQR: interquartile range, CRP: C-reactive protein  
 
 
age of 74 years, as compared with 62 years (p=0.001) among patients with-
out antiplatelet therapy. Since specific diseases and medical conditions asso-
ciated with indications for antiplatelet therapy have an age-dependent preva-
lence this was an expected finding and is in agreement with previous studies 
dealing with chronic antiplatelet therapy in IE (51, 53, 118, 119). In paper 
III, where only episodes of NVE were studied, patients on warfarin tended to 
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be older than patients not on warfarin, but the differences did not reach sta-
tistical significance for median ages (69 vs. 64 years, p=0.058). Patients with 
PVE were significantly older than patients with NVE (71 vs. 64 years, 
p<0.001)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Number of patients with infective endocarditis divided by 10-year age 
intervals. Total number of episodes 797. 
 
 
Sex differences  
In the total cohort of 797 IE episodes, 33% (264) were seen in women, 
Women were, on average, older than men (68 vs. 65 years, p=0.02). The 
proportion of definite IE did not differ significantly between the sexes. Mi-
tral valve involvement was more common in women than in men (54 vs. 
46%, p=0.029) but the presence and length of vegetations did not differ be-
tween the sexes. Contrary to a study concerning sex differences in IE by 
Aksoy et al. (50) there was no statistically significant difference between the 
frequency of comorbid conditions between women and men. A higher pro-
portion of IE episodes in women were caused by S. aureus as compared with 
the proportion in men (29% vs. 20%, p=0.003).  
 
In the total cohort, CVC were seen in 26% of the female episodes as com-
pared with 20% of the male episodes (p=0.06). When definite episodes were 
studied separately (paper II), the higher CVC frequency in women was sta-
tistically significant (30% vs. 22%, p=0.039). However, when the patients 
were stratified for microbial etiology, the CVC frequency did not differ be-
tween the sexes. This is contrasted by the findings in a study of 260 S. 
aureus IE by Roder et al. in which women tended to have more neurological 
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complications than men (55). Among episodes of definite IE, cardiac surgery 
during hospital stay was performed in 40% of the women vs. 44% of the 
men (n.s.). There was no statistically significant difference in in-hospital 
mortality between women and men (17% vs. 13%, n.s.), but 12-month mor-
tality was higher in women (31% vs. 24%, p=0.031), similar to the findings 
of Thuny et al. (58). 
4.2 Microbiology  
The most commonly found pathogens in the total cohort of 797 patients were 
viridans group streptococci (including S. bovis) seen in 29% of the episodes 
(figure 4). S. aureus was the etiological agent in 23% of all cases and in two 
episodes MRSA strains were identified. In paper II, where definite IE cases 
were studied separately, the S. aureus etiological fraction was 25% 
(168/684). This is consistent with the 28% S. aureus IE among 1213 definite 
IE cases from European countries prospectively included from 2000-2005 in 
the International Collaboration on Endocarditis (ICE) study (42). In paper I, 
the proportion of S. aureus IE among study patients was 25%. 
 
 
 
Figure 4. Microbiological etiology of 797 left-sided infective endocarditis episodes. 
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Negative blood cultures were seen in 12% of all episodes, and 58% of the 
blood culture negative episodes were classified as possible. This is compati-
ble with an analysis of culture negative IE reported in the National Swedish 
Endocarditis registry from 1995-2004, where the proportion of culture nega-
tive episodes was 12%, and 75% were classified as possible IE (57). In a 
prospective epidemiological study from Gothenburg and Borås, Sweden 
(1984-1996), the proportion of culture negative IE was higher, 20%, and 
only one fifth of the culture negative IE cases were classified as definite IE 
(149). The combined secondary and tertiary referral center characteristics of 
the including sites in our study probably conferred a selection bias affecting 
the proportion of blood culture negative IE episodes. 
 
Patients with enterococcal IE were significantly older (median 72 years) than 
patients with IE of other etiologies (median 60-65 years, p=0.01) except for 
coagulase-negative staphylococci (median 68 years), where the difference 
was not significant (figure 5). Enterococcal IE has been more prevalent in 
studies specifically concerning IE in older patients (41, 150). Prosthetic 
valve endocarditis (n=210) were caused by coagulase-negative staphylococci 
in 17% of the cases, in another 17% of the cases by viridans group strepto-
cocci, and in 19% each by S. aureus and enterococci. Of coagulase-negative 
staphylococcal IE 51% were PVE as compared with 24% PVE episodes with 
other pathogens (p<0.001).  
 
 
Figure 5. Median age (interquartile range) among 797 IE episodes divided by 
pathogen. 
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4.3 Cerebrovascular complications 
Symptomatic cerebrovascular complications 
Cerebrovascular complications with concomitant neurological symptoms 
were diagnosed in 22% (177) of the IE episodes in the total cohort. The inci-
dence of CVC in papers II and III was 25% in each. This higher figure is 
explained by the fact that CVC were diagnosed more often during definite IE 
episodes (paper II) as compared with possible episodes (25% vs. 7%, 
p<0.001), and that significantly more CVC were detected in episodes of 
NVE as compared with PVE (24% vs. 16%, p=0.008). Median ages did not 
differ significantly between patients with and without CVC. The CVCs were 
divided into three major groups; ischemic (including both established infarc-
tions and TIA), hemorrhagic, and infectious complications depending on the 
type of sign or lesion presented. The proportion of episodes where two or 
more types of cerebral lesions were detected was 4% in the total cohort. 
More than one neurological symptom was displayed by 15% of the 60 pa-
tients in paper I, although one of the symptoms dominated in each patient’s 
initial presentation. Neurological symptoms were present on admission for 
IE in three quarters of the patients with symptomatic CVC (paper I: 76%, 
paper II: 73%, paper III: 74%). Totally 17% of all patients experienced a 
CVC during admission (half recurrent CVC, half first time CVC) in paper I 
compared to 8% in papers II-III. The frequency of patients who underwent 
cardiac surgery after hosiptal admission for IE did not differ between pa-
tients with and without CVC in the total cohort (42% vs. 38%, n.s.). 
 
Neurological symptoms were displayed by a significantly higher proportion 
of the patients in paper I (35%) than in papers II-III (25%, p=0.003). The 
high proportion of patients found to have symptomatic cerebral complica-
tions in paper I could be explained by the additional clinical diagnostic ef-
forts in the study with repeatedly performed standardized neurological ex-
aminations of the patients included, apart from the radiological and neuro-
chemical investigations also undertaken. A higher diagnostic sensitivity of 
this procedure could be assumed as compared with the routine physical and 
neurological examinations performed in patients in the other parts of the 
study.  
 
In paper I patients were not included consecutively owing to late transfer of 
a considerable proportion of IE patients from other hospitals, the possible 
inclusion period of the study thereby being passed. Some patients were also 
reluctant to participate in a study involving additional investigations in the 
early period of this often unexpected and serious disease. The non-
consecutive inclusion of IE patients might have impacted on the number of 
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patients with neurological symptoms included, but no selection of neurologi-
cally symptomatic IE patients was done during the study period. 
 
Ischemic infarctions and TIA  
Ischemic infarction was the most common type of CVC, seen in 15% 
(120/797) of the episodes in the total study cohort. In paper I patients with 
neurological symptoms had ischemic lesions in 18 episodes, corresponding 
to 30% of the 60 patients included. Infarctions among the neurologically 
symptomatic patients were verified using MRI and release of brain damage 
markers in 11 cases, only by MRI findings in six cases and by isolated eleva-
tion of NFL and GFAP in one case. There were multiple ischemic lesions on 
MRI in 10 patients, ranging from three to more than 10 in each patient. The 
sizes varied from punctuate to 3 cm, and in one patient there was a more 
specific pattern of septic embolism with early stages of abscess formation. 
The lesions were distributed in various parts of the brain including the corti-
cal, subcortical, cerebellar and thalamic regions.  
 
In paper III, where 587 NVE episodes were studied separately, 96 cerebral 
ischemic infarctions verified by CT or MRI were found out of 144 episodes 
with symptomatic CVC (67%) (table 3). The size and localizations of these 
infarctions were not recorded systematically in the total study cohort, but all 
patients were neurologically symptomatic and the majority displayed focal 
or multifocal neurological symptoms. 
 
Table 3. Types of cerebral lesions in 144 native valve endocarditis episodes with 
cerebrovascular complications (paper II). 
 Number of NVE epi-
sodes with CVC 
n=144  
Proportion of all NVE 
episodes 
n=587 
Ischemic infarction 96 (67%) 16% 
Transient ischemic attack  20 (14%) 3% 
Hemorrhagic lesion 14 (10%) 2% 
Ruptured mycotic aneu-
rysm 
2 (1%) 0.3% 
Cerebral infection 38 (26%) 6% 
More than one type of 
cerebral lesion  
26 (18%) 4% 
 
Among the 282 Swedish patients with NVE included in paper III, 16% suf-
fered a symptomatic ischemic infarction verified by CT or MRI. Twenty 
percent of these 44 patients died during index hospitalization, 18% had ma-
jor sequelae (hemiparesis, aphasia) and 25% minor sequelae (minor weak-
ness, dysphasia, cognitive impairment) at hospital discharge. Studies on neu-
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rological recovery in IE patients are scarce but our figures can be compared 
with the findings of Ruttmann et al. (52) in a study of 214 surgically treated 
IE patients. Thirty percent of the patients in that study had cerebral compli-
cations prior to cardiac surgery. Overall 54% of the patients with preopera-
tive cerebral lesions achieved full neurological recovery (in-hospital mortal-
ity 17%), but a worse prognosis was seen in patients with large cerebral in-
farctions and patients with multiple types of neurological complications. 
Stroke in IE patients was concluded to have a favorable prognosis as com-
pared with stroke resulting from other causes. 
 
A TIA was diagnosed in 3% of the 587 NVE episodes in paper III and in one 
out of 60 IE episodes (2%) in paper I. Similar incidences of TIA were found 
by Heiro et al. (5%) at a Finnish teaching hospital with IE patients included 
from 1980-1996 (49), and in a study by Thuny et al. (6%) among 496 pro-
spectively studied definite left-sided IE episodes 1990-2005 at two French 
referral centers (72). Since a TIA, by definition, only gives transient neuro-
logical signs, a risk for underdiagnosis accompanies this condition, but the 
specificity in the diagnosis of TIA could also be questioned. 
Cerebral hemorrhage  
Cerebral bleeding was detected in 14 out of the 587 NVE episodes (2%) and 
in two additional patients with PVE, the frequency of cererbral hemorrhage 
in PVE thereby being 1% (2/210). Accordingly, in 16 of the 797 episodes in 
the total cohort (2%) some degree of cerebral bleeding was found, and 75% 
of these complications had already occurred before admission to hospital. 
The cerebral hemorrhage was characterized as primary intracerebral in seven 
cases, caused by a ruptured mycotic aneurysm in two cases, complicating a 
primary infarction in six cases, and accompanying a brain abscess in one 
case. Patients suffering from cerebral hemorrhagic complications in IE were 
younger than patients with other types of CVC (median 54 vs. 65 years, 
p=0.024). The causative pathogen was S. aureus in 56% (9/16) of the IE 
cases with a hemorrhagic complication as compared with 49% (59/120) S. 
aureus IE among patients with ischemic infarctions (n.s.). In-hospital mor-
tality among patients with intracerebral bleeding complications was 38% 
(6/16), not significantly different from the in-hospital mortality of 25% 
(41/161) seen in patients with other types of CVC. In paper I the incidence 
of symptomatic cerebral bleeding was 2% (one patient) while minor hemor-
rhagic components not influencing the management of the patients were 
found in another five patients.  
 
Mycotic aneurysms were detected in three patients in the total cohort, two of 
whom presented with a subarachnoid hemorrhage on admission. In the third 
patient, MRI detected an aneurysm without signs of bleeding that healed 
during antibiotic therapy. Blood cultures were negative in two cases and 
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grew Cardiobacterium hominis in the third case. None of the patients with 
mycotic aneurysms died during admission. One of the patients, with a rup-
tured mycotic aneurysm on admission, underwent cardiac surgery on treat-
ment day 71 owing to progressive aortic insufficiency. Two intracerebral 
mycotic aneurysms had been coiled prior to the cardiac operation. An addi-
tional patient presented with a ruptured mycotic aneurysm four months after 
the completion of antibiotic therapy for aortic NVE caused by Salmonella 
enteritidis. This illustrates a well-known risk of late cerebral complications 
in IE (47, 151).  
 
Meningitis and brain abscess 
Signs of cerebral infection were found in 40 out of 797 patients (5%) in the 
total cohort, and in 20 there were other concomitant neurological signs. 
Cerebral CT diagnosed a brain abscess in three patients and the remaining 37 
were characterized as episodes of meningitis by findings in lumbar puncture. 
The CSF pleocytosis was usually moderate and ranged from 11 to 3 000 x 
106 white blood cells/mL with a median of 99 (IQR 25-134) x 106 white 
blood cells/mL. In two cases culture of CSF was positive, but most lumbar 
punctures were performed after the institution of antibiotics. In one case, 
CSF culture grew S. aureus (polymorphnuclear leucocytes 96 x 106 /mL) and 
in one case Streptococcus oralis (polymorphnuclear leucocytes 3 000 x 
106/mL). In the total cohort lumbar puncture was only performed in patients 
with clinical suspicion of meningitis or occasionally on the basis of clinical 
suspicion of subarachnoid bleeding (one case with sudden severe pain in the 
occipital part of the head), and when no contraindications for this investiga-
tion were perceived. CSF-NFL and CSF-GFAP were not used to detect cere-
bral parenchymatous involvment in papers II and III. A normal CSF finding 
was only seen in four patients, probably indicating a low tendency to per-
form lumbar puncture in this type of patients. In-hospital mortality in pa-
tients with meningitis as the only cerebral complication was 11% (2/18) and 
one additional patient had minor sequelae at hospital discharge. In paper I 
isolated meningitis was found in two out of 60 patients (3%). 
Encephalopathy 
The clinical entity referred to as encephalopathy in earlier series of IE (54, 
55, 77, 82, 152) has been documented clinically in our study cohort as pa-
tients presenting with a mixed picture of altered consciousness, variable 
degree of meningism and minor focal neurological signs on neurological 
examination, but the term encephalopathy is not used in papers II and III. 
The inclination to perform neuroradiological examinations, e.g. CT scan of 
the brain, to further characterize various neurological symptoms in IE pa-
tients was high during the study period. The number of cerebral events 
thereby classified as infarctions instead of encephalopathy was probably 
higher in our study than in studies including patients from the 1980s (49, 54, 
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77) when CT examinations assumedly were less common. In still earlier 
studies, such as the study by Pruitt et al. published in 1978 (47), the high in-
hospital mortality rates in IE patients with neurological complications (58%) 
and the considerable proportion of post-mortem examinations executed in 
these patients (>90%) facilitated more precise diagnosis. The detected inci-
dence of major cerebral infarctions was 17% in that study, and an additional 
11% of the patients were found to have microembolic ischemic lesions. Pa-
tients with microembolic lesions presented with altered levels of conscious-
ness and fluctuating neurological signs, in accord with the clinical descrip-
tion of encephalopathy. 
 
In paper I a more thorough characterization of patients with encephalopathic 
neurological manifestations was possible, and all these patients presented 
with confusion and/or altered consciousness and minor focal signs. Alto-
gether six out of 60 patients (10%) were considered to be encephalopathic, 
and the median age of these patients was 78 years as compared with 54 years 
in patients presenting with other neurological signs (n.s.). In all six patients 
with the clinical picture of encephalopthy there were multiple ischemic le-
sions demonstrated on MRI, and increased levels of GFAP and NFL were 
detected in CSF, illustrating the embolic nature of these lesions and the in-
volvement of parenchymatous CNS damage. 
4.4 Factors related to the incidence of cerebrovascular 
complications  
Antiplatelet therapy (paper II) 
In paper II the aim was to study the relationship between previously estab-
lished antiplatelet therapy and the incidence of cerebrovascular complica-
tions in left-sided definite IE episodes. Antiplatelet therapy was established 
prior to IE diagnosis in 23% of the 684 IE episodes in patients included in 
this part of the study. No difference in the incidence of CVC during IE was 
detected between patients with and without previously established antiplate-
let therapy (24% vs. 25%, OR 0.9, 95% CI 0.6-1.4). To adjust for possible 
confounding variables a multiple logistic regression model was used, and 
variables that were significantly associated with both occurrence of CVC 
and to the use of antiplatelet therapy were included. After adjustment for 
congestive heart failure, vegetation length, pathogen and CRP level no sig-
nificant relation between antiplatelet therapy and CVC incidence was found 
either (aOR 0.8, 95% CI 0.48-1.5). 
 
The possibility of a reduced embolic risk owing to use of antiplatelet therapy 
during the prediagnostic development of IE has been debated (51, 53, 153, 
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154) while in a prospective study, the initiation of antiplatelet therapy after 
IE diagnosis was found not to reduce the embolic risk (117). A study on 
specific influence of antiplatelet therapy on mortality rate (118) and of ASA 
on the rate of acute valvular replacement surgery in S. aureus IE (119) has 
been published recently. Only one small previous study has focused on the 
role of antiplatelet therapy in relation to cerebral complications (155).  
Anticoagulant therapy in native valve endocarditis (paper III) 
In paper III, including episodes of NVE, 8% (48/587) of the patients were on 
oral anticoagulants (warfarin) upon admission. There was, as expected, a 
significantly higher prevalence of atrial flutter among patients on warfarin as 
compared with patients not on warfarin (37% vs. 12%, p<0.001). Surgical 
rates did not differ between patients with and without warfarin on admission 
for IE. 
 
Symptomatic CVC were significantly less frequent in NVE patients on war-
farin than in patients not on this treatment, i.e. in 6% vs. 26% (OR 0.2, 95% 
CI 0.06-0.6, P=0.006). In the warfarin group all CVC were established on 
admission, while 7% of the patients without warfarin experienced a first 
CVC during antibiotic treatment. The reduction in CVC rate consisted of a 
lower number of non-hemorrhagic events, while the incidence of hemor-
rhagic complications did not differ significantly between patients with and 
without warfarin therapy (figure 6). After adjustment for age, sex, S. aureus 
etiology, history of congestive heart failure or previous IE episode, vegeta-
tion length and CRP level, a significantly lower incidence of CVC prevailed 
among patients on warfarin (aOR 0.26, 95% CI 0.07-0.94, p=0.04). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cerebrovascular complications in 587 left-sided native valve endocarditis 
episodes in patients with and without warfarin therapy  
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The aim in paper III was to do a specific analysis of the relation between 
ongoing therapy with vitamin K antagonists and the incidence of CVC in IE 
affecting native valves. This design was chosen in order to avoid confound-
ing from inherent differences in (i) CVC rate between NVE and PVE, (ii)  
PVE affecting different types of valve prostheses (mechanical, bioprosthetic, 
homograft) and (iii) effects on CVC rate between oral anticoagulants and 
heparin analogues.  
 
Anticoagulant therapy and prosthetic valve endocarditis 
In the total cohort of 797 patients there were 210 PVE not separately ana-
lyzed in papers I-III. As earlier mentioned, the CVC incidence was lower 
among PVE cases than in NVE (16% vs. 24%, p=0.008). The incidence 
tended to be lower in bioprosthetic PVE (13%, 13/98) than in mechanical 
PVE (18%, 20/112) but this difference was not statistically significant. War-
farin use on admission for PVE was frequent (67%), and, as expected, it was 
more frequent in PVE on mechanical valve prostheses compared to PVE on 
bioprostheses (90%, vs. 41%, p<0.001). CVC incidence in PVE did not dif-
fer between patients with and without warfarin therapy (17% [24/141 vs. 
13% [9/69], n.s.), and this was similar in both mechanical and biological 
PVE. These findings evoke the hypothesis that embolic events in PVE and 
NVE have different predictors and favor separate analysis of the disease 
entities. Some recent studies have found a trend towards fewer CVC in PVE 
compared to NVE (49, 55, 65) or a lower rate of systemic major embolism in 
PVE (156), while the incidence of cerebral complications in NVE and PVE 
did not differ in other studies (48, 54, 72). 
Microbial etiology and CVC 
Patients with S. aureus IE suffered from cerebral complications significantly 
more frequently than patients with IE caused by other pathogens. The CVC 
incidence in S. aureus IE was 49% (89/182) in the total cohort, which corre-
sponded to 52% among both definite IE episodes (paper II) and NVE epi-
sodes (paper III). In table 4 unadjusted OR for CVC divided by pathogen in 
definite IE episodes are shown (paper II). Enterococcal IE carried the lowest 
CVC risk, significantly different from the risk seen in culture-negative IE 
(OR 2.8, 95% CI 1.1–7.0) and S. aureus IE (OR 8.5, 95% CI  4.4-16.8). In 
both papers I and III, S. aureus etiology remained a significant risk factor for 
symptomatic CVC in the multivariable models, with an adjusted odds ratio 
of 6.1 (95% CI 1.5-24.3) and 6.3 (95% CI 3.8-10.4), respectively. 
 
IE episodes complicated with meningitis had a different etiological pattern, 
since this manifestation was seen more often in IE caused by non-viridans 
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Table 4. Odds ratio for cerebrovascular complications divided by pathogen in 684 
definite infective endocarditis episodes. 
Pathogen % CVC OR 95% CI for 
OR 
Enterococci  
(n=108) 
11% (n=12) reference - 
Coagulase-negative  
staphylococci (n=59) 
14% (n=8) 1.3 0.5 - 3.3 
Viridans streptococci 
(n=214) 
15% (33) 1.5 0.7 – 2.9 
Other streptococci  
(n=47) 
19% (n=9) 1.9 0.7 – 4.9 
Miscellaneous  
(n=49) 
20% (n=10) 2.1 0.8 – 5.1 
Culture negative  
(n=39) 
26% (n=10) 2.8* 1.1 – 7.0 
S. aureus  
(n=168) 
52% (n=87) 8.5* 4.4 – 16.8 
* p<0.05. 
 
 
streptococci (15%, 7/47) and in S. aureus IE (14%, 24/168) compared to 
episodes of other etiologies (1%, 6/469, p<0.001). Cerebral hemorrhage 
occurred in 5% of culture-negative IE (2/39) and 5% of S. aureus IE (9/168), 
but only the latter was significantly different from the incidence of cerebral 
hemorrhage seen in IE of other etiologies (1%, 5/477, p=0.003) (paper II).  
 
If the analysis of CVC frequency was performed on the total cohort of pa-
tients including possible IE cases, the proportion of patients with culture-
negative IE suffering any CVC (including hemorrhage) was lower, since 
definite IE diagnosis in culture negative IE relies on signs of embolism and 
other minor criteria. 
4.5 Echocardiography 
Incidence of vegetations 
Vegetations were established in 75% of the 760 episodes in the total cohort 
that were possible to evaluate for the presence of vegetation. A symptomatic 
CVC was diagnosed in 25% of the episodes with vegetation on echocardi-
ography as compared with in 12% of episodes without detected vegetations, 
p<0.001. Among episodes of NVE (paper III), a statistically significant dif-
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ference in CVC rate between episodes with and without vegetations was 
detected as well (27%, vs. 14%, p=0.003). In paper II, where definite IE 
episodes were studied separately, the trend was similar but the difference 
was no longer statistically significant (26% vs. 18%, p=0.06). This discrep-
ancy could be explained by the construction of the modified Duke criteria, 
since an embolic event is considered a minor criterion for IE. A suspected IE 
episode without an echocardiographic major criterion is frequently classified 
as definite, owing to the presence of embolism together with e.g. positive 
blood cultures, a predisposing condition and fever. This implies a higher 
incidence of CVC among IE episodes without an echocardiographically de-
tected vegetation, when only definite episodes are studied. In paper I, a vege-
tation was observed in 70% (42/60) of the patients. A symptomatic CVC 
occurred in 45% of the patients with a vegetation, as compared with in 11% 
of patients without a vegetation, p=0.02.  
Size of vegetation 
IE episodes complicated with symptomatic CVC had significantly longer 
vegetations, median 10 mm (IQR 6-16) vs. 8 mm (IQR 5-12), p<0.001, when 
the total cohort was analyzed. This difference was statistically significant 
among definite IE episodes in paper II (median 10 mm [IQR 6-16] vs. 8 mm 
[IQR 5-12], p<0.001) and among NVE cases studied in paper III (median 11 
mm [IQR 6-16] vs. 9 mm [IQR 5-13], p=0.006). Vegetation length differed 
in all types of CVC as compared with episodes without CVC except for TIA, 
where median vegetation lengths were similar in cases with and without the 
complication. Between IE cases with cerebral hemorrhage and cases without 
any CVC the difference in vegetation length did not reach statistical signifi-
cance, which was probably an effect of the limited number of patients with 
this complication (data not shown).  
 
In paper III the vegetation length in NVE episodes was found to be an inde-
pendent predictive factor for CVC using a multivariable model. After ad-
justment for age, sex, S.aureus etiology, history of congestive heart failure or 
previous IE, and CRP level, vegetation length remained significantly associ-
ated with a higher incidence of CVC with an adjusted OR of 1.04 (95% CI 
1.01-1.07, p=0.005).  
 
In paper I there was also a significant association between vegetation length 
and incidence of both symptomatic and total cerebral embolism (including 
silent emboli). Median vegetation length in episodes with symptomatic CVC 
as compared with episodes without was 12 mm (IQR 8-16) vs. 8 mm (IQR 
6-11), p=0.001. A similar correlation was seen for the incidence of total 
CVC (10 mm |IQR 8-15] vs. 5 mm [IQR 4-10), p<0.001). In multivariable 
logistic regression analysis the only variable correlated to an increased risk 
of both clinically symptomatic CVC (adjusted OR 1.17 [95% CI 1.05-1.30], 
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p=0.005) and total CVC (adjusted OR 1.23 [95% CI 1.08-1.39], p=0.001) 
was the length of vegetation. As mentioned above, S aureus etiology also 
conferred a higher risk for clinical cerebral embolism but not total cerebral 
embolism. In the multivariable analysis, the area under the ROC curve was 
calculated for the discriminating variables (weighted sum of vegetation 
length and S. aureus etiology, and only vegetation length) and found to be 
0.811 and 0.782, respectively.  
Additional aspects on echocardiographic findings 
In 37 patients the echocardiographic examinations were inconclusive regard-
ing the presence of vegetations, e.g. in cases with severe regurgitation and 
perforated heart valves, intracardiac abscesses or concomitant ruptured chor-
dae tendinae. These episodes were regarded as “missing values” in the 
analysis of the relationship between the presence of vegetation and the inci-
dence of CVC. Five of the episodes were classified as possible, 22 were 
definite according to surgical findings, six were definite attributable to the 
presence of an intracardic abscess, and the remaining four patients were 
classified as definite without the echocardiographic criterion fulfilled. In 
another 65 cases the echocardiographic examinations (all TEE) defined the 
presence but not the size of vegetation. All these cases were classified as 
definite, and 31 underwent cardiac surgery. The remaining 34 episodes were 
seen in patients with varying types of predisposing cardiac valve anomalies. 
Paravalvular involvement was found in 112 (14%) of the IE episodes, in 
63% of these together with a vegetation. Paravalvular complications were 
significantly more frequent in PVE than NVE (p<0.001).  
Multivariable modeling 
After multivariable analysis (paper III) additional variables found to corre-
late to CVC incidence among NVE patients were history of congestive heart 
failure (aOR 0.22; 95% CI 0.1-0.52) and history of previous IE episode 
(aOR 0.1; 95% CI 0.01-0.79), both associated with a lower incidence of 
CVC. 
4.6 Silent cerebral embolism 
In paper I the incidence of silent CVC was found to be 30% (18/60) when 
MRI of the brain and CSF analysis were used to detect lesions (figure 7). 
The MRI lesions in patients with silent cerebral embolism were all small 
ischemic infarctions with a maximum size of 1 cm, and the findings were 
multiple in 40% of the patients. Out of the 27 patients with no IE related 
pathological MRI findings, 14 had other types of lesions, mainly minor old 
infarctions or white matter lesions. 
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Figure 7. Incidence and distribution of cerebrovascular complications among 60 IE 
patients (paper I). Circles represent the patients with cerebrovascular complications 
detected by each method. 
 
Only one of the patients in the study had a history of previous stroke, and no 
clinical or silent signs of CVC correlated to the current IE episode were de-
tected in this patient. In one patient, previously operated on for falx men-
ingeoma, minor residual meningeomal tissue and gliosis were found on MRI 
in combination with a new ischemic infarction in the cerebellum. In another 
patient a Chiari malformation not previously known was found, and this 
patient also had signs of silent CVC verified by both MRI and CSF findings. 
In yet another patient with clinically obvious cerebral embolism also verified 
with MRI and CSF findings, a previously diagnosed hypophyseal adenoma 
was seen. None of the patients in the study had a history of or signs attribut-
able to other neurological diseases known to be associated with elevations in 
brain damage markers or specific MRI lesion (131, 133, 138). 
 
Elevated levels of NFL (figure 8) and/or GFAP (figure 9) in CSF as markers 
of parenchymatous brain damage was seen in 24 patients, 12 of whom had 
no concomitant neurological signs. In all symptomatic patients both CSF-
NFL and CSF-GFAP were elevated above the reference levels, and elevated 
levels of polymorphnuclear cells were found in seven patients as well. 
Among the 12 patients with silent cerebral embolism detected on the basis of 
CSF findings, eight were detected from elevations in brain damage markers 
only (CSF-NFL and CSF-GFAP elevated in five, only CSF-NFL in three). 
There were no statistically significant differences between CSF-NFL or 
CSF-GFAP levels in patients with symptomatic and silent CVC, respec-
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tively, but for CSF-NFL the highest values were seen in symptomatic pa-
tients. For CSF-GFAP the highest value was detected in a patient with silent 
CVC and no ischemic lesion identified on MRI. 
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Figure 8. CSF-NFL levels in infective endocarditis patients according to presence and 
type of cerebrovascular complication (CVC). 
Reference levels: < 59 years: < 250 ng/L, 60-69 years: < 380 ng/L, > 70 years: < 750 ng/L
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Figure 9. CSF-GFAP levels in infective endocarditis patients according to presence and 
type of cerebrovascular complication (CVC). 
Reference levels: 21-59 years: < 750 ng/L, > 60 years: < 1250 ng/L
43
tis
 46 
The kinetics of NFL and GFAP elevations in CSF after acute CNS damage 
differ considerably, with the highest CSF-GFAP elevations detected after 
24-48 hours and normalization within less than three weeks. For CSF-NFL 
there is a gradual increase peaking after a few weeks and normalizing 
months after the acute insult. This is consistent with the isolated CSF-NFL 
increment found in three neurologically asymptomatic patients, where the 
assumption is that the expected concomitant GFAP elevation had already 
passed when the sample was taken. In the neurologically symptomatic pa-
tients the first LP was probably performed closer in time to the embolic 
event as compared with in the patients with silent CVC.  
 
No LP was performed in 21 patients for reasons of concomitant anticoagula-
tion (9), other contraindications (4), early surgery before LP was possible 
(3), refusal (3), and technical problems (2). CSF findings were normal in 13 
patients.  
4.7 Mortality 
In-hospital mortality was 13% in the total cohort, 14% among definite cases 
(paper II) and 12% among NVE cases (paper III). Infective endocarditis 
patients with cerebral manifestation showed significantly higher in-hospital 
mortality than patients without such complications, 27% vs. 9%, p<0.001 
(total cohort). Of all patients who died during hospitalization (104) for IE, 
45% had a CVC prior to succumbing. The different in-hospital mortality 
between patients experiencing neurological complications were statistically 
significant when infarctions (30% vs. 9%, p<0.001) and cerebral hemorrhage 
(38% vs. 9%, p=0.006) were analyzed separately. For episodes complicated 
with meningitis the picture was different, and in patients with meningitis as 
the sole neurological manifestation, no significantly different in-hospital 
mortality was seen compared to patients without any CVC (11% vs. 9%, 
n.s.). For patients with isolated TIA there was a trend toward higher mortal-
ity (18% vs. 9%, n.s.). In paper I in-hospital mortality was only 2%. 
 
In-hospital mortality was significantly correlated to age and increased for 
each 10-year interval from 50 to 70 years of age (<50 years: 5%, 51-60 
years: 11%, 60-69 years: 14%, >70 years: 17%, p=0.002). Higher in-hospital 
mortality was seen for patients with CVC in all age groups, but for patients 
<50 years this trend was not significant (10% vs. 4%, n.s.). In-hospital mor-
tality has been shown to correlate to age and CVC rate in other studies (39, 
41, 42, 52, 150, 157).  
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Long-term outcome 
Cerebral complications influenced long-term outcome. Among the 684 epi-
sodes of definite IE a survival analysis using Kaplan-Meier procedure 
showed a significantly lower survival rate among patients with CVC during 
the follow-up period (log rank test, p=0.004) (figure 10). Follow up varied 
from 114 days to 4473 days (12.2 years) with a median of 3.6 years. After 10 
years the survival rate was 35% among patients who experienced a CVC 
during the initial IE episode and 50% in patients without CVC. The analysis 
after 10 years was based on 25 survivors of 589 alive at hospital discharge. 
The detrimental long-term impact of neurological complications has been 
shown in other studies (40, 72, 78) but the low 10-year survival rates in all 
patients also reflects the high median ages in IE patients in the present series. 
 
Figure 10. Kaplan-Meier analysis of long-term survival among IE patients with and 
without a cerebrovascular complication during the initial IE episode.  
CVC: cerebrovascular complication, Cum survival: cumulative survival rate. 
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5 General considerations 
Incidence of symptomatic cerebral manifestations 
The symptomatic cerebral complication rate of 22% found in this large co-
hort of adult IE patients, with ischemic stroke as the dominant lesion, is in 
accord with recent studies focusing on cerebral complications (48, 49, 72). 
The higher incidence of symptomatic CVC found in paper I might reflect 
more sensitive clinical examinations in that study as well as a higher aware-
ness of neurological symptoms in IE patients during the study period, but 
inclusion bias could not be ruled out. Unchanged frequencies of cerebral 
complications have been asserted since the preantibiotic era of IE, but fig-
ures are not comparable without further evaluation of the demographic char-
acteristics of patients included in the different studies. The evolving epide-
miology and varying definitions of IE and of cerebral complications, chang-
ing diagnostic procedures, different study designs and the influence of selec-
tion bias have to be considered in these comparisons.  
 
In the preantibiotic era the proportion of IE episodes caused by streptococci, 
especially the viridans group streptococci but also beta-hemolytic strepto-
cocci and pneumococci, was much higher, and the natural history of the dis-
ease could be observed in all patients, since no therapeutic measures were 
possible. The rate of cerebral complications in IE episodes caused by viri-
dans group streptococci was around 40-50% in studies prior to the mid-
1940s (92, 146), which is comparable with the CVC rate found in S. aureus 
IE in our cohort, but much higher than the rates of CVC seen in viridans 
group streptococcal IE today. The enhanced possibilities for early diagnose 
of IE and for effective treatment have probably decreased the rate of CVC in 
streptococcal IE.  
 
Regarding S. aureus IE, the development is less clear since the relative and 
probably also the absolute incidence of this disease has increased since the 
introduction of penicillin (34, 158) parallel to enhanced detection of IE and 
improved initial management of septic patients. Cerebral complications in S. 
aureus IE are high in modern studies (34, 55, 159) and were also described 
as high in early IE patient series (46). The improved diagnostic methods 
might have given a paradoxical increase of cerebral events in S. aureus IE, 
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since more patients with an inherently high risk of CVC survive the early 
septic phase and are therefore diagnosed with IE. 
Cerebrovascular complications 
In the present studies, all CNS complications were regarded as eminating 
from a cerebrovascular pathogenesis, based on the assumption that cerebral 
involvement in IE is mainly caused by septic micro- and macroembolism 
from valvular vegetations. Ths view has also been employed by others (94, 
95). Cerebral emboli have been shown to cause a variety of pathogenetic 
processes and a variable pattern of often coexisting cerebral injuries (47, 89, 
90, 92, 160). Our findings of multiple cerebral lesions are in accord with 
earlier observations. However, the incidence of stroke within the first month 
after a bacteremia, also without concomitant IE, has been shown to be higher 
than in the general population (161, 162). Complementary pathogenetic 
mechanisms, such as the presence of a hyperocoagulable state (163) or the 
presence of anti-phospholipid antibodies (164) have been suggested.  
Silent cerebral embolism 
Silent embolism both to the brain and to other parts of the vascular tree has 
been shown in previous studies (47, 56, 58, 66). However, the number of 
silent CVCs found in our study was higher than in previous studies. Our 
findings are in accordance with the reported findings in an ongoing French 
study also using MRI of the brain in IE patients to detect silent cerebral em-
bolism and to assess the diagnostic and therapeutic impact of MRI findings. 
Interim analysis of the MRI findings in 130 IE patients in that study showed 
an even higher incidence of total CVC (symptomatic and silent events), 
reaching 82%, with 12% of the included IE patients experiencing concomi-
tant neurological symptoms (pers. comm. Xavier Duval). The MRI protocol 
used in the French study differed from the protocol in our series, and they 
report multiple microbleeds as a typical finding in IE patients.  
 
The impact of silent embolism on mortality was not analyzed in paper I, but 
the prognostic influence of silent cerebral embolism has been evaluated by 
Thuny et a. (72) in a French prospective observational study including 496 
left-sided definite IE patients from 1990-2005. Cerebral CT scan was used 
systematically in all patients from 1993. In that study IE patients with silent 
CVC and TIA had a mortality risk not significantly different from IE pa-
tients without CVC, while patients with symptomatic stroke had signifi-
cantly higher in-hospital and long-term mortality. Stroke remained a signifi-
cant predictor of death after adjustment for other factors found to correlate to 
mortality.  
 
In our total cohort of patients the in-hospital mortality in IE cases compli-
cated with isolated meningitis was not significantly higher than in patients 
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with no cerebral complications, which supports the theory that the size and 
type of CNS damage is a main prognostic factor. In another prospective 
study published by Millaire et al. in 1997 (66), with systematic search for 
cerebral and peripheral emboli in IE, embolic events of all types were found 
in 51% of the patients but were not associated with significant attributable 
mortality. It has also been shown that IE patients with large symptomatic 
preoperative cerebral emboli have a worse prognosis after cardiac surgery 
than IE patients with small symptomatic lesions (52). The results in our stud-
ies verify previous findings showing that both symptomatic and silent cere-
bral complications in IE are common and that symptomatic events signifi-
cantly influence in-hospital and long-term outcome while the prognostic 
impact of silent cerebral embolism is not clear. Potential improvements in 
the management of IE after detection of silent CVC have been suggested, 
e.g. modifications of antibiotic treatment (use of antibiotics with high CNS 
penetration), surgical management (episodes with large vegetations and si-
lent CVC) or possible modifications in anticoagulant treatment. However, 
present evidence does not favor the need for routine search for asymptomatic 
cerebral complications in IE, but further investigations will guide future 
recommendations. 
Antiplatelet therapy 
Potential effects of antiplatelet agents, mainly ASA, in IE have been sug-
gested since the late 1970s (114). Animal models of IE have outlined several 
protective effects of antiplatelet agents during IE, e.g. impaired vegetation 
growth, enhanced sterilization of vegetations, reduced adherence of S. 
aureus to sterile vegetations after preexposure to ASA, and down regulation 
of virulence factors (109, 110, 113, 165). A prospective randomized con-
trolled trial of the effect of high-dose ASA (325 mg) initiated after IE diag-
nosis in 60 patients showed no reduction of systemic embolic events as 
compared with the frequency of embolic events in 55 IE patients given pla-
cebo (117). On the contrary, a retrospective analysis of embolic events in 
600 IE patients found a significantly lower embolic frequency in patients 
with established use of antiplatelet agents during the development of IE (53). 
Three additional studies did not verify a significantly lower incidence of 
embolic events in patients on established antiplatelet agents (51, 118, 119). 
However, reduced three-month mortality in patients on previously estab-
lished antiplatelet therapy was found in one of the studies, and a reduced 
need for cardiac surgery was found in another. These effects were postulated 
to be specific for S. aureus IE. A reduced incidence of catheter-associated S. 
aureus bacteremia has also been found in hemodialysis patients treated with 
325 mg ASA, implicating a clinically useful anti-staphylococcal effect of 
ASA (166).  
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In the analysis of CVC incidence in paper II no correlation was found be-
tween prior established use of antiplatelet therapy and the frequency of 
CVC, and unadjusted 12-month mortality was significantly higher in patients 
on antiplatelet agents. However, when adjusted for other variables signifi-
cantly associated with 12-month mortality, no significant relationship re-
mained between 12-month mortality and antiplatelet therapy. Our findings 
thus do not support the hypothesis that antiplatelet therapy influences em-
bolic tendency in IE patients, and no statistically significant conclusions 
could be drawn regarding the influence of antiplatelet therapy on mortality. 
However, important variables with previously shown major impact on mor-
tality in IE, e.g. development of new or worsening congestive heart failure 
during IE, were not retained in our model. Additionally, the study was not 
designed to evaluate other possible benefits of antiplatelet therapy in IE. 
Despite the large number of patients in our study, the number of S. aureus IE 
episodes might have been too small to evaluate specific interactions between 
S. aureus and antiplatelet agents.  
Hemorrhagic cerebral complications 
Hemorrhagic complications were few in the present series, reaching 2% 
symptomatic bleeding events both in the total cohort of IE patients and in the 
patients systematically investigated using MRI and CSF analysis in paper I. 
No increase was detected among patients on antiplatelet therapy or oral anti-
coagulants. The number of detected ruptured cerebral mycotic (infectious) 
aneurysms was less than 0.5% in the total cohort of IE patients and only one 
patient with an unruptured aneurysm was found. Similar low rates of rup-
tured mycotic aneurysms have been found in other recent studies (49, 54, 
72), but data supporting the occurrence of a considerably higher number of 
unruptured and clinically silent aneurysms that heal during antibiotic therapy 
have also been presented (47, 167, 168). The detected number of silent aneu-
rysms will probably increase in the future following the use of further en-
hanced neuroradiological imaging, such as e.g. MR angiography. The low 
but prolonged risk of aneurysm rupture after antibiotic therapy has been 
completed, as seen in one of the patients in our study, is well recognized in 
previous studies (76, 151). 
Oral anticoagulant therapy 
The proportion of NVE patients on warfarin who suffered a CVC was sig-
nificantly lower than the proportion of patients not on warfarin who suffered 
a CVC (6% vs. 26%, p=0.006). This was an unexpected finding since the 
only previous study separately addressing the issue of anticoagulation in 
NVE patients (96) found cerebrovascular accidents significantly more fre-
quently among anticoagulated patients as compared with non-anticoagulated 
patients. The CVC proportion in that restrospective study remained signifi-
cantly higher among anticoagulated NVE patients when cerebral hemor-
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rhagic complications were analyzed separately, but not when ischemic cere-
bral complications (including CVC of unclear origin but not TIA) were ana-
lyzed. Among 269 NVE patients in that study, including patients from 1970-
1987, cerebral hemorrhagic complications were seen in 5% and cerebral 
ischemic infarctions in 7% of the patients. The number of ischemic events 
was relatively low as compared with most other series, which implies very 
restricted diagnostic criteria for ischemic cerebrovascular accidents or possi-
ble selection bias.  
 
Other previous studies addressing the relationship between anticoagulant 
therapy and cerebral embolic complications in IE patients have included 
very few anticoagulated patients (47) or have mainly focused on patients 
with PVE (97, 169-171). These studies have included patients over an ex-
tended period of time, and Leport et al. (169) found better management of 
anticoagulant treatment among patients in the later part of the study. It is not 
known whether improved general management of anticoagulant therapy in 
IE patients has since been achieved. One recently published study primarily 
addressing the effects of antiplatelet therapy in IE (118) detected a signifi-
cantly higher incidence of hemorrhagic stroke among patients who were on 
warfarin prior to IE diagnosis, although no more detailed information was 
given. An increasing frequency of anticoagulant associated intracerebral 
hemorrhage was reported during the 1990s in patients with anticoagulant 
therapy for any indication (172). 
 
The lower CVC rate among NVE patients on warfarin therapy in our study 
remained significant after adjustment for microbiological etiology and vege-
tation length, indicating that warfarin treatment may diminish the liability for 
embolization independently from vegetation length. Fibrin formation plays 
important roles during the development of IE, both in the attachment of bac-
teria to the surface of the vegetations and in the formation of a protective 
layer against host defense mechanisms within the vegetation. A disturbance 
in fibrin formation could therefore possibly influence both the development 
of IE and the frequency of embolism. Only a few experimental studies with 
diverging results were published in this area in the 1970s (7), while the ques-
tion has not been addressed in later studies and merits further attention in 
future studies. 
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 6 Conclusions 
• Cerebrovascular complications were seen in 65% of patients with 
left-sided infective endocarditis when sensitive diagnostic methods 
were used, but almost half of these were clinically silent. 
 
• Prior established antiplatelet therapy gave no protection against 
cerebral complications in infective endocarditis. After adjustment 
for covariables antiplatelet therapy had no significant impact on 
mortality. 
 
• Ongoing oral anticoagulation with warfarin on admission for native 
valve endocarditis was associated with lower risk of cerebrovascular 
complications. 
 
• Staphylococcus aureus etiology and vegetation length as detected 
using echocardiography were each correlated to a higher risk of 
cerebrovascular complications in infective endocarditis.  
 
• Cerebral hemorrhagic complications were few. Antiplatelet therapy, 
warfarin therapy and prosthetic valve endocarditis conferred no 
higher frequency of these complications. 
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7 Svensk sammanfattning 
 
Infektiös hjärtklaffsinfektion är en relativt ovanlig men livshotande sjukdom. 
I Sverige diagnosticeras cirka 550 fall årligen. Risk för hjärtklaffsinfektion 
är högre hos individer med skador på hjärtklaffarna eller inopererade hjärt-
klaffsproteser. Personer med kvarliggande intravenösa infarter, t ex hemodi-
alyspatienter, har också förhöjd risk liksom individer med intravenöst miss-
bruk.  
 
Vid hjärtklaffsinfektion finns det bakterier i blodet, som fått fäste på en 
hjärtklaff och gett upphov till infekterade koagel där, s.k. vegetationer. 
Hjärtklaffen kan skadas och börja läcka, vilket kan medföra hjärtsvikt. Akut 
hjärtkirurgi behövs i c:a 30% av alla fall. En annan vanlig och allvarlig 
komplikation vid hjärtklaffsinfektion är s.k. embolisering, då små infektera-
de fragment från vegetationerna lossnar och förs med blodet till olika organ 
med åtföljande skador. Detta sker i 20-60% av episoderna och hjärnan drab-
bas mest frekvent, vilket medför olika typer av neurologiska symtom och 
skador. Kliniskt tysta (asymtomatiska) embolier förekommer också. Skador-
na i hjärnan är av varierande typ. Vanligast är hjärninfarkt orsakad av för-
hindrad blodförsörjning till en del av hjärnan, men infektion i hjärnan eller 
hjärnhinnorna och hjärnblödning förekommer också. Olika typer av skador 
kan uppstå parallellt. 
 
Syftet med avhandlingens studier var att undersöka frekvensen symtomgi-
vande och tysta embolier till hjärnan samt att kartlägga faktorer associerade 
med ökad och minskad emboliseringsrisk. I delstudie I undersöktes 60 pati-
enter med magnetresonanstomografi (MR) och provtagning av ryggmärgs-
vätska med analys av markörer för hjärnskada. Andelen patienter som drab-
bades av symtomgivande neurologiska komplikationer var 35% och därut-
över påvisades tyst embolisering till hjärnan hos ytterligare 30%. 
 
I delstudie II undersöktes om mediciner som minskar blodets levringsförmå-
ga via hämning av blodplättarnas funktion (vanligen acetylsalicylsyra, ASA) 
minskar risken för symtomgivande embolisering till hjärnan. Andelen pati-
enter som drabbades av neurologiska komplikationer var likartad hos patien-
ter med och utan blodplättshämmande medicinering. 
 
I delstudie III påvisades en minskad andel symtomgivande embolier till 
hjärnan hos patienter som stod på blodförtunnande medicinering i form av 
warfarin, ett potent antikoagulerande läkemedel som verkar via minskad 
produktion av ett flertal koagulationsfaktorer. Hjärtklaffsinfektion orsakad 
av Staphylococcus aureus samt större uppmätt vegetationslängd medförde 
större risk för neurologiska komplikationer. 
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